[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100548148":3},{"organization":4,"armGroups":7,"interventions":45,"overallOfficials":56,"centralContacts":11,"locations":60,"responsibleParty":74,"collaborators":11,"id":76,"slug":77,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":11,"eligibilityCriteria":82,"healthyVolunteers":83,"sex":84,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":11,"studyType":90,"phases":91,"briefSummary":93,"conditions":94,"keywords":96,"overallStatus":102,"whyStopped":11,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":111},{"fullName":5,"class":6},"Celgene","INDUSTRY",[8,14,17,20,23,26,29,32,35,38,41],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1: Cohort 1 BMS-986365 Dose 1","EXPERIMENTAL",null,[13],"Drug: BMS-986365",{"label":15,"type":10,"description":11,"interventionNames":16},"Part 1: Cohort 2 BMS-986365 Dose 2 Formulation 1",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"Part 1: Cohort 2 BMS-986365 Dose 3 Formulation 2",[13],{"label":21,"type":10,"description":11,"interventionNames":22},"Part 1: Cohort 3 BMS-986365 Dose 4",[13],{"label":24,"type":10,"description":11,"interventionNames":25},"Part 1: Cohort 6 BMS-986365 Dose 5",[13],{"label":27,"type":10,"description":11,"interventionNames":28},"Part 1: Cohort 7 BMS-986365 Dose 6",[13],{"label":30,"type":10,"description":11,"interventionNames":31},"Part 1: Cohort 8 BMS-986365 Dose 7",[13],{"label":33,"type":10,"description":11,"interventionNames":34},"Part 1: Cohort 9 BMS-986365 Dose 8",[13],{"label":36,"type":10,"description":11,"interventionNames":37},"Part 2: Cohort 4 BMS-986365 Dose 9 Fasted",[13],{"label":39,"type":10,"description":11,"interventionNames":40},"Part 2: Cohort 4 BMS-986365 Dose 10 Fed",[13],{"label":42,"type":10,"description":11,"interventionNames":43},"Part 2: Cohort 5 BMS-986365 Dose 11 Fasted Followed by Rabeprazole + Rabeprazole and BMS-986365",[13,44],"Drug: Rabeprazole",[46,53],{"type":47,"name":48,"description":49,"armGroupLabels":50,"otherNames":51},"DRUG","BMS-986365","Specified dose on specified days",[9,15,18,21,24,27,30,33,39,36,42],[52],"CC-94676",{"type":47,"name":54,"description":49,"armGroupLabels":55,"otherNames":11},"Rabeprazole",[42],[57],{"name":58,"affiliation":58,"role":59},"Bristol-Myers Squibb","STUDY_DIRECTOR",[61],{"facility":62,"status":11,"city":63,"state":64,"zip":65,"country":66,"countryCode":67,"cosmosGeoPoint":68,"geoPoint":73,"contacts":11},"Local Institution - 0001","Lenexa","Kansas","66219","United States","US",{"type":69,"coordinates":70},"Point",[71,72],-94.73357,38.95362,{"lat":72,"lon":71},{"type":75,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100548148","phase-1-study-to-evaluate-safety-drug-levels-food-and-relative-bioavailability-of-bms-986365-in-healthy-adult-male-participants-100548148",false,"NCT06417229","Study to Evaluate Safety, Drug Levels, Food and Relative Bioavailability of BMS-986365 in Healthy Adult Male Participants","A Phase 1, Two-part, Open-label Single Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of BMS-986365, Food and Proton Pump Inhibitor Effects, and Relative Bioavailability of BMS-986365 Capsule Compared to Tablet Formulation in Healthy Adult Male Participants","Inclusion Criteria:\n\n* Healthy adult male participants as determined by no clinically significant deviations from normal in medical history, physical examination, vital signs, ECGs, echocardiogram, or clinical laboratory assessments as determined by the investigator.\n* Body mass index (BMI) of 18.0 to 32.0 kg\u002Fm\\^2, inclusive.\n\nExclusion Criteria:\n\n* Any significant acute or chronic illness.\n* Prior history of heart failure, ischemic heart diseases, serious cardiac arrythmias, or prolonged QT interval.\n* History of allergy\u002Fhypersensitivity to any component (including excipients) of BMS-986365 study interventions or related compounds.\n* Other protocol-defined inclusion\u002Fexclusion criteria apply.",true,"MALE","18 Years","60 Years",{"count":88,"type":89},102,"ACTUAL","INTERVENTIONAL",[92],"PHASE1","The purpose of this study is to evaluate the safety, tolerability, drug levels, food effects and relative bioavailability of BMS-986365 in healthy male participants.",[95],"Healthy Participants",[48,97,98,99,52,100,101],"Pharmacokinetics","Relative Bioavailability","Healthy Male Volunteers","Food Effect","Proton Pump Inhibitor","COMPLETED","2025-03-04",{"date":105,"type":89},"2025-03-06",{"date":107,"type":89},"2024-05-28",{"date":109,"type":89},"2025-02-19",{"name":5,"class":6},1]